U.S. Supreme Court rules against Amgen bid to revive cholesterol drug patents
By John Kruzel WASHINGTON (Reuters) -The U.S. Supreme Court on Thursday ruled against Amgen Inc in its bid to revive patents on its cholesterol-lowering drug Repatha in a legal clash with French rival Sanofi SA. The 9-0 ruling upheld a lower court’s decision that had invalidated Amgen’s patents on the grounds that the Thousand Oaks, …
U.S. Supreme Court rules against Amgen bid to revive cholesterol drug patents Read More »










